Comparison
BPC-157 vs KPV
Both are healing & repair, so the meaningful differences are in kinetics, evidence and regulatory status.
| BPC-157 | KPV | |
|---|---|---|
| Class | Healing & repair | Healing & repair |
| Evidence | Animal models only | Animal models only |
| Human trials | None published | None published |
| Half-life | ~4 hours | ~1-2 hours |
| Reported range | 200-500 mcg | 200-500 mcg |
| Frequency | 1-2x daily, often near the injury site | 1-2x daily |
| Routes | Subcutaneous, Oral, Intramuscular | Oral, Subcutaneous, Topical |
| FDA approved | No | No |
| Research use only | Yes | Yes |
| Banned in sport | Yes | No |
| Studied for | Tendon and ligament injury research, Gastrointestinal healing research, Soft tissue repair | Inflammatory bowel research, Skin inflammation, Gut barrier research |
| Reported side effects | Injection-site reactions, Transient nausea, Headache, Dizziness | Injection-site reactions, Mild gastrointestinal upset |
BPC-157
BPC-157 is a stable 15-amino-acid sequence derived from body protection compound, a protein found in human gastric juice. Animal work reports accelerated healing across tendon, ligament, muscle, bone and gastrointestinal tissue, with proposed mechanisms including upregulation of VEGF-driven angiogenesis, modulation of the nitric oxide system, and increased fibroblast migration and growth-factor receptor expression. The evidence base is almost entirely rodent. No adequately powered human trial has been published, which is the central fact about this compound and should lead every page about it.
KPV
KPV is the terminal three residues of alpha-melanocyte-stimulating hormone. It retains the parent hormone anti-inflammatory activity, apparently by entering cells and interfering with NF-κB and MAPK signalling to reduce proinflammatory cytokine production, but it does not activate melanocortin-1 receptors and therefore does not cause tanning. Most research is in inflammatory bowel models, where oral and rectal delivery have been examined.
BPC-157 vs KPV: common questions
What is the difference between BPC-157 and KPV?
Both are healing & repair. BPC-157: A synthetic pentadecapeptide derived from a gastric protein, and the most searched compound in the peptide category. KPV: The C-terminal tripeptide of alpha-MSH, which keeps the anti-inflammatory activity without the pigmentation effects.
Which has stronger evidence, BPC-157 or KPV?
They sit at the same evidence level: animal models only. BPC-157 has about 0 human studies and KPV about 0.
Are BPC-157 and KPV FDA approved?
Neither is FDA approved for any indication.
References
Regulatory and primary sources
- PubChem compound record (CID 9941957) ↗ · structure, identifiers, synonyms
- WADA Prohibited List ↗ · current year
- FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
- CAS Registry Number 137525-51-0 ↗ · chemical identity
- PubChem compound record (CID 13294447) ↗ · structure, identifiers, synonyms
Published literature
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.Cell Tissue Res 2019.PubMed 30915550 · doi:10.1007/s00441-019-03016-8
- BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.Curr Pharm Des 2018.PubMed 29998800 · doi:10.2174/1381612824666180712110447
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
- Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?.Arthroscopy 2025.PubMed 39265666 · doi:10.1016/j.arthro.2024.09.005
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
- BPC 157 and blood vessels.Curr Pharm Des 2014.PubMed 23782145 · doi:10.2174/13816128113199990421
- The neuroimmunomodulatory peptide alpha-MSH.Ann N Y Acad Sci 2000.PubMed 11268347 · doi:10.1111/j.1749-6632.2000.tb05386.x
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.J Sports Med Phys Fitness 2026.PubMed 41880199 · doi:10.23736/S0022-4707.26.17773-1
- The neuropeptide alpha-MSH in host defense.Ann N Y Acad Sci 2000.PubMed 11268348 · doi:10.1111/j.1749-6632.2000.tb05387.x
- Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.Adv Exp Med Biol 2010.PubMed 21222263 · doi:10.1007/978-1-4419-6354-3_8
- Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.Int J Med Sci 2025.PubMed 41209547 · doi:10.7150/ijms.118118
- Mechanisms of antiinflammatory action of the neuroimmunomodulatory peptide alpha-MSH.Ann N Y Acad Sci 1998.PubMed 9629264 · doi:10.1111/j.1749-6632.1998.tb09576.x
- Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.Drug Discov Today 2025.PubMed 41241376 · doi:10.1016/j.drudis.2025.104535
- Peptide modulation of inflammatory processes within the brain.Neuroimmunomodulation 1998.PubMed 9730684 · doi:10.1159/000026335
Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.